Get the Stockscreener App
52.91
1.75%
0.91
Tarsus Pharmaceuticals Inc stock is traded at $52.91, with a volume of 708.14K.
It is up +1.75% in the last 24 hours and up +13.59% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
See More
Previous Close:
$52.00
Open:
$50.52
24h Volume:
708.14K
Relative Volume:
1.08
Market Cap:
$2.02B
Revenue:
$17.39M
Net Income/Loss:
$-135.89M
P/E Ratio:
-15.65
EPS:
-3.38
Net Cash Flow:
$-123.00M
1W Performance:
+0.78%
1M Performance:
+13.59%
6M Performance:
+100.34%
1Y Performance:
+164.42%
1-Day Range:
$50.20
$53.62
1-Week Range:
$50.20
$56.77
52-Week Range:
$18.99
$56.77
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
52.91 | 2.02B | 17.39M | -135.89M | -123.00M | -4.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 52-Week HighHere's What Happened - MarketBeat
When the Price of (TARS) Talks, People Listen - Stock Traders Daily
Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS)🤭 Experimente a diversão no C333Bet - Oficjalny Portal Gminy Brzesko
Wellington Management Group LLP Acquires 18,019 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals: Worthy Of A Small Bet (NASDAQ:TARS❌ Ilumine seu dia com Estrela BRT - Oficjalny Portal Gminy Brzesko
Tarsus Pharmaceuticals Insider Lowered Holding By 16% During Last Year - Simply Wall St
Lord Abbett & CO. LLC Acquires 131,636 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks - Seeking Alpha
Tarsus Pharmaceuticals' SWOT analysis: eye care stock's growth trajectory By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals' SWOT analysis: eye care stock's growth trajectory - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap DownTime to Sell? - MarketBeat
The Manufacturers Life Insurance Company Has $1.08 Million Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - Defense World
Tarsus Pharmaceuticals Stock Hits 52-Week High at $53.02 By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals Stock Hits 52-Week High at $53.02 - Investing.com
Tarsus Pharmaceuticals: Early Rollout Exceeding Expectations (NASDAQ:TARS) - Seeking Alpha
Charles Schwab Investment Management Inc. Buys 28,130 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
23,199 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by Verition Fund Management LLC - MarketBeat
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet - MSN
Tarsus stock Buy rating intact as Guggenheim tracks Xdemvy's Demodex blepharitis launch - Investing.com UK
Vestal Point Capital LP Invests $7.57 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Trims Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Analysts Set Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) PT at $54.20 - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Ally Bridge Group NY LLC Makes New $10.59 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Midday Stock Roundup: Chipotle stock up as chain announces 2% hike in menu prices - Orange County Business Journal
Tarsus Pharmaceuticals' SWOT analysis: XDEMVY success drives stock outlook - Investing.com
Mutual of America Capital Management LLC Invests $4.29 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Jennison Associates LLC Buys 698,712 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) - MarketBeat
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade - MSN
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
22,493 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Purchased by GSA Capital Partners LLP - MarketBeat
What is Lifesci Capital's Forecast for TARS FY2024 Earnings? - MarketBeat
Tarsus Pharmaceuticals Appoints Kate Goodrich, MD, to its Board of Directors - Vision Monday
US$65.33That's What Analysts Think Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Worth After These Results - Simply Wall St
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.3%Here's What Happened - MarketBeat
Trend Tracker for (TARS) - Stock Traders Daily
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
The Goldman Sachs Group Forecasts Strong Price Appreciation for Tarsus Pharmaceuticals (NASDAQ:TARS) Stock - MarketBeat
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript - Insider Monkey
Tarsus Pharmaceuticals stock target upgraded, holds buy on strong sales By Investing.com - Investing.com UK
Paradigm Biocapital Advisors LP Increases Stake in Tarsus Pharma - GuruFocus.com
Prudential Financial Inc's Strategic Acquisition in Tarsus Pharm - GuruFocus.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Hits New 1-Year High After Analyst Upgrade - Defense World
Tarsus Pharmaceuticals stock soars to 52-week high of $52 - Investing.com
Tarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High After Analyst Upgrade - MarketBeat
Tarsus Pharmaceuticals stock soars to 52-week high of $52 By Investing.com - Investing.com UK
Tarsus Pharmaceuticals (NASDAQ:TARS) Given New $65.00 Price Target at Oppenheimer - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):